Disruptive Dose with Matt Holland

Chief Operating Officer | Healio

May 2026

In this DHCG Disruptive Dose, Mark Bard speaks with Matt Holland, Chief Operating Officer at Healio, about AI’s transformation of medical publishing and HCP information consumption. Holland emphasizes that while AI enables faster content delivery and personalization, medical publishers must maintain rigorous editorial standards and clinical accuracy as core differentiators. He discusses the tension between speed and verification, explaining why credible sources matter more when AI-generated summaries proliferate. Holland offers perspective on adapting to AI-driven search and consumption patterns while preserving the clinical rigor and editorial independence that distinguish professional medical content from algorithmic aggregation.